FDA批准AJOVY用于预防儿童和青少年的偏头痛,这是CGRP对抗者的首例。 FDA approves AJOVY for migraine prevention in kids and teens, a first for CGRP antagonists.

林业发展局已核准AJOVY(fremanezumab-vfrm),以防止6-17岁、体重至少45公斤的儿童和青少年的癫痫性偏头痛。 The FDA has approved AJOVY® (fremanezumab-vfrm) for the prevention of episodic migraines in children and adolescents aged 6-17 who weigh at least 45 kilograms. 这使AJOVY成为第一个而且是唯一一个与胆碱酯酶基因有关的铅化物(CGRP)对抗者,获准供儿科和成人使用。 This makes AJOVY the first and only calcitonin gene-related peptide (CGRP) antagonist approved for pediatric use and adults. AJOVY每月通过注射管理,为年轻病人提供了一种新的治疗选择,有可能减少偏头痛日的频率。 Administered monthly via injection, AJOVY offers a new treatment option for young patients, potentially reducing the frequency of migraine days.